<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02389621</url>
  </required_header>
  <id_info>
    <org_study_id>1423M0634</org_study_id>
    <secondary_id>2014-004942-91</secondary_id>
    <nct_id>NCT02389621</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures</brief_title>
  <acronym>L-PLUS 2</acronym>
  <official_title>A Phase 3 Randomised, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of S-888711 (Lusutrombopag) for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures (L-PLUS 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shionogi Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to compare the efficacy of lusutrombopag with placebo
      for the treatment of thrombocytopenia in patients with chronic liver disease who are
      undergoing elective invasive procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of 3 periods: a screening period (up to 28 days prior to randomization), a
      treatment period of 7 days (Days 1 to 7 during which study drug is to be administered for 4
      to 7 days), and a posttreatment period (through 28 days posttreatment).

      Once-daily treatment with lusutrombopag 3 mg or placebo is to commence on Day 1 and continue
      for up to 7 days. Platelet count is to be determined on Days 5, 6, and 7 prior to
      administration of study drug; if a participant meets the administration stopping criterion
      (ie, platelet count ≥ 50 × 10⁹/L with an increase of ≥ 20 × 10⁹/L from baseline), no
      additional dose of study drug is to be administered. The planned invasive procedure is to be
      performed in the posttreatment period between Days 9 and 14. Platelet count for determination
      of the need for platelet transfusion is to be determined on or after Day 8, but no more than
      2 days prior to the invasive procedure; a platelet transfusion is required if the platelet
      count is &lt; 50 × 10⁹/L.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2015</start_date>
  <completion_date type="Actual">April 19, 2017</completion_date>
  <primary_completion_date type="Actual">April 5, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Required No Platelet Transfusion Prior to the Primary Invasive Procedure and No Rescue Therapy For Bleeding From Randomization Through 7 Days After the Primary Elective Procedure</measure>
    <time_frame>From Randomization to 7 days after the invasive procedure, up to approximately 21 days.</time_frame>
    <description>Participants were considered as meeting the primary endpoint if all of the following conditions were satisfied:
Required no platelet transfusion from the date of randomization through at least 7 days after the primary invasive procedure
Did not receive the following rescue therapy for bleeding from the date of randomization through 7 days after the primary invasive procedure
Platelet preparations
Other blood preparations, including red blood cells and plasma
Volume expanders
Underwent an invasive procedure. Participants who received at least one platelet transfusion prior to the primary invasive procedure, received at least one rescue therapy for bleeding from the date of randomization through 7 days after the primary invasive procedure, discontinued from the study before undergoing the primary invasive procedure, or did not undergo an invasive procedure were considered as not meeting the primary endpoint.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Required no Platelet Transfusion During the Study</measure>
    <time_frame>From Day 1 to end of the posttreatment period, 35 days.</time_frame>
    <description>Participants who did not undergo the invasive procedure were considered as having received platelet transfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Response</measure>
    <time_frame>From Day 1 to the end of the posttreatment period, 35 days.</time_frame>
    <description>A response was defined as a platelet count of ≥ 50 × 10⁹/L with an increase of ≥ 20 × 10⁹/L from Baseline at any time during the study. Participants who met this response criterion only after platelet transfusion were considered as nonresponders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Increase in Platelet Count to ≥ 50 × 10⁹/L</measure>
    <time_frame>From Day 1 to the end of the posttreatment period, 35 days.</time_frame>
    <description>The duration of the increase in platelet count was defined as the number of days during which the platelet count was maintained as ≥ 50 × 10⁹/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Increase in Platelet Count to ≥ 50 × 10⁹/L by Platelet Transfusion Status</measure>
    <time_frame>From Day 1 to the end of the posttreatment period, 35 days.</time_frame>
    <description>The duration of the increase in platelet count was defined as the number of days during which the platelet count was maintained as ≥ 50 × 10⁹/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Required Rescue Therapy for Bleeding During the Study</measure>
    <time_frame>From Day 1 to the end of the possttreatment period, 35 days.</time_frame>
    <description>Participants who received rescue therapy for bleeding events during the study. Platelet preparations, other blood preparations (including red blood cells and plasma), and volume expanders were considered as rescue therapy for bleeding events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Specified Total Number of Platelet Transfusions</measure>
    <time_frame>From Day 1 to the end of the posttreatment period, 35 days.</time_frame>
    <description>The number of transfusions administered to each patient were collected over the duration of the trial. The data are presented as the number of patients with the highest total number of transfusions followed by the next highest number of transfusions, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Platelet Count Over Time</measure>
    <time_frame>Baseline and Days 5, 6, 7, 8, 10, 12, 14, 17, 21, 28, and 35.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>From first dose of study drug to 28 days after the last dose, 35 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Lusutrombopag</measure>
    <time_frame>Day 5, predose and 2, 4, 6, 8, 24, and 48 hours post-dose (24 and 48 hours post-dose = Day 6 and Day 7 prior to dose on that day).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of Lusutrombopag</measure>
    <time_frame>Day 5, predose and 2, 4, 6, 8, 24, and 48 hours post-dose (24 and 48 hours post-dose = Day 6 and Day 7 prior to dose on that day).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve Over the Dosing Interval τ (AUC0-τ) for Lusutrombopag</measure>
    <time_frame>Day 5, predose and 2, 4, 6, 8, 24, and 48 hours post-dose (24 and 48 hours post-dose = Day 6 and Day 7 prior to dose on that day).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Clearance (CL/F) of Lusutrombopag</measure>
    <time_frame>Day 5, predose and 2, 4, 6, 8, 24, and 48 hours post-dose (24 and 48 hours post-dose = Day 6 and Day 7 prior to dose on that day).</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">215</enrollment>
  <condition>Chronic Liver Disease</condition>
  <condition>Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Lusutrombopag</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lusutrombopag 3 mg once daily for up to 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily for up to 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lusutrombopag</intervention_name>
    <description>Tablets for oral administration</description>
    <arm_group_label>Lusutrombopag</arm_group_label>
    <other_name>S-888711</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets for oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to understand the study and comply with all study procedures.

          2. Willing to provide written informed consent prior to Screening.

          3. Male or female.

          4. 18 years of age or older at the time of signing informed consent.

          5. Platelet count &lt; 50 × 10^9/L at baseline on Day 1 prior to randomization.

          6. Undergoing an elective invasive procedure.

          7. In the opinion of the investigator, able to meet study requirements.

          8. Male patients who are sterile or who agree to use an appropriate method of
             contraception (including use of a condom with spermicide) from Screening to completion
             of the Post-treatment Period.

          9. Female patients who are not postmenopausal or surgically sterile need to agree to use
             a highly effective contraception (including contraceptive implant, injectable
             contraceptive, combination hormonal contraceptive [including vaginal rings],
             intrauterine contraceptive device or vasectomised partner) from Screening to
             completion of the Post-treatment Period. Barrier method with or without spermicide,
             double barrier contraception and oral contraceptive pill are insufficient methods on
             their own.

        Exclusion Criteria:

          1. Any of the following diseases:

               -  hematopoietic tumor

               -  aplastic anemia

               -  myelodysplastic syndrome

               -  myelofibrosis

               -  congenital thrombocytopenia

               -  drug-induced thrombocytopenia

               -  generalized infection requiring treatment except for viral liver disease

               -  immune thrombocytopenia.

          2. History of splenectomy.

          3. History of liver transplantation.

          4. Any of the following at Screening:

               -  hepatic encephalopathy uncontrolled by drugs

               -  ascites uncontrolled by drugs.

          5. Portal vein tumor embolism.

          6. Known to be positive for the human immunodeficiency virus.

          7. Past or present thrombosis or prothrombotic condition (e.g., cerebral infarction,
             myocardial infarction, angina pectoris, coronary artery stent placement, angioplasty,
             coronary artery bypass grafting, congestive heart failure [New York Heart Association
             Grade III/IV], arrhythmia known to increase the risk of thromboembolic events [atrial
             fibrillation], pulmonary thromboembolism, deep vein thrombosis, or disseminated
             intravascular coagulation syndrome).

          8. History or evidence of any of the following diseases:

               -  congenital thrombotic disease (eg, antithrombin deficiency, protein C deficiency,
                  protein S deficiency, or coagulation factor [Factor V Leiden] mutation)

               -  acquired thrombotic disease (eg, antiphospholipid antibody syndrome, paroxysmal
                  nocturnal hemoglobinuria, hyperhomocysteinemia, or increased factor VIII)

               -  Budd Chiari syndrome.

          9. Portal vein thrombosis based on ultrasound, computed tomography (CT), or magnetic
             resonance imaging (MRI) within 28 days prior to randomization or a history of portal
             vein thrombosis.

         10. Absence of hepatopetal blood flow in the main trunk of the portal vein as demonstrated
             by Doppler ultrasonography within 28 days prior to randomization.

         11. History or evidence of disease associated with a risk of bleeding (e.g., coagulation
             factor deficiency or von Willebrand factor deficiency).

         12. Bleeding score at randomization ≥ Grade 2 according to the World Health Organization
             (WHO) Bleeding Scale.

         13. Any of the following drugs or therapies within 90 days prior to randomization:

               -  anticancer drugs

               -  interferon preparations

               -  radiation therapy

               -  exsanguination

               -  other thrombopoietin receptor agonist

               -  any investigational agent.

         14. Any invasive procedure within 14 days prior to randomization.

         15. Blood transfusion within 14 days prior to randomization.

         16. Prior treatment with lusutrombopag (S-888711).

         17. Pregnancy or lactation.

         18. Known or suspected ongoing, active alcohol or substance abuse. Patients with a recent
             history who the investigator feels are able to comply with the study procedures and
             medications will be allowed to participate.

         19. Considered ineligible by the investigator for any other reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <role>Study Director</role>
    <affiliation>Shionogi</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>March 10, 2015</study_first_submitted>
  <study_first_submitted_qc>March 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <results_first_submitted>August 27, 2018</results_first_submitted>
  <results_first_submitted_qc>August 27, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 25, 2018</results_first_posted>
  <disposition_first_submitted>March 21, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>March 21, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 23, 2018</disposition_first_posted>
  <last_update_submitted>October 1, 2018</last_update_submitted>
  <last_update_submitted_qc>October 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Elective invasive procedures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 3, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT02389621/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT02389621/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 138 sites in 22 countries (Argentina, Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Hungary, Israel, Italy, Poland, Republic of Korea, Romania, Russian Federation, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, and United States of America).</recruitment_details>
      <pre_assignment_details>The study consisted of a screening period (up to 28 days), a treatment period of 7 days, and a posttreatment period (through 28 days posttreatment).
Randomization was stratified by the primary invasive procedure (ie, liver ablation/coagulation or other invasive procedures) and baseline platelet count (&lt; 35 × 10⁹/L or ≥ 35 × 10⁹/L).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lusutrombopag</title>
          <description>Lusutrombopag 3 mg once daily for up to 7 days.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo once daily for up to 7 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Posttreatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other - Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lusutrombopag</title>
          <description>Lusutrombopag 3 mg once daily for up to 7 days.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo once daily for up to 7 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="108"/>
            <count group_id="B2" value="107"/>
            <count group_id="B3" value="215"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.2" spread="11.6"/>
                    <measurement group_id="B2" value="56.1" spread="11.0"/>
                    <measurement group_id="B3" value="55.7" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="188"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="171"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not provided</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Planned Invasive Procedure</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Liver ablation/ coagulation</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Platelet Count</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt; 35 × 10⁹/L</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 35 × 10⁹/L</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Required No Platelet Transfusion Prior to the Primary Invasive Procedure and No Rescue Therapy For Bleeding From Randomization Through 7 Days After the Primary Elective Procedure</title>
        <description>Participants were considered as meeting the primary endpoint if all of the following conditions were satisfied:
Required no platelet transfusion from the date of randomization through at least 7 days after the primary invasive procedure
Did not receive the following rescue therapy for bleeding from the date of randomization through 7 days after the primary invasive procedure
Platelet preparations
Other blood preparations, including red blood cells and plasma
Volume expanders
Underwent an invasive procedure. Participants who received at least one platelet transfusion prior to the primary invasive procedure, received at least one rescue therapy for bleeding from the date of randomization through 7 days after the primary invasive procedure, discontinued from the study before undergoing the primary invasive procedure, or did not undergo an invasive procedure were considered as not meeting the primary endpoint.</description>
        <time_frame>From Randomization to 7 days after the invasive procedure, up to approximately 21 days.</time_frame>
        <population>All randomized participants (intent-to-treat population)</population>
        <group_list>
          <group group_id="O1">
            <title>Lusutrombopag</title>
            <description>Lusutrombopag 3 mg once daily for up to 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Required No Platelet Transfusion Prior to the Primary Invasive Procedure and No Rescue Therapy For Bleeding From Randomization Through 7 Days After the Primary Elective Procedure</title>
          <description>Participants were considered as meeting the primary endpoint if all of the following conditions were satisfied:
Required no platelet transfusion from the date of randomization through at least 7 days after the primary invasive procedure
Did not receive the following rescue therapy for bleeding from the date of randomization through 7 days after the primary invasive procedure
Platelet preparations
Other blood preparations, including red blood cells and plasma
Volume expanders
Underwent an invasive procedure. Participants who received at least one platelet transfusion prior to the primary invasive procedure, received at least one rescue therapy for bleeding from the date of randomization through 7 days after the primary invasive procedure, discontinued from the study before undergoing the primary invasive procedure, or did not undergo an invasive procedure were considered as not meeting the primary endpoint.</description>
          <population>All randomized participants (intent-to-treat population)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.8" lower_limit="55.0" upper_limit="73.8"/>
                    <measurement group_id="O2" value="29.0" lower_limit="20.6" upper_limit="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistical tests were performed at a 2-sided significance level of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted using the stratification factors of platelet count at randomization and the planned primary invasive procedure.</method_desc>
            <param_type>Difference</param_type>
            <param_value>36.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>24.9</ci_lower_limit>
            <ci_upper_limit>48.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Required no Platelet Transfusion During the Study</title>
        <description>Participants who did not undergo the invasive procedure were considered as having received platelet transfusion.</description>
        <time_frame>From Day 1 to end of the posttreatment period, 35 days.</time_frame>
        <population>All randomized participants (intent-to-treat population)</population>
        <group_list>
          <group group_id="O1">
            <title>Lusutrombopag</title>
            <description>Lusutrombopag 3 mg once daily for up to 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Required no Platelet Transfusion During the Study</title>
          <description>Participants who did not undergo the invasive procedure were considered as having received platelet transfusion.</description>
          <population>All randomized participants (intent-to-treat population)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.0" lower_limit="53.1" upper_limit="72.1"/>
                    <measurement group_id="O2" value="29.0" lower_limit="20.6" upper_limit="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A gatekeeping procedure was employed for sequentially testing the prespecified important secondary endpoints, identified as the most clinically relevant endpoints. If the primary endpoint was statistically significant, the secondary endpoints were tested at the 0.05 level (2-sided) in sequence.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted for the stratification factors of platelet count at randomization and the planned primary invasive procedure.</method_desc>
            <param_type>Difference</param_type>
            <param_value>34.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>22.8</ci_lower_limit>
            <ci_upper_limit>46.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Response</title>
        <description>A response was defined as a platelet count of ≥ 50 × 10⁹/L with an increase of ≥ 20 × 10⁹/L from Baseline at any time during the study. Participants who met this response criterion only after platelet transfusion were considered as nonresponders.</description>
        <time_frame>From Day 1 to the end of the posttreatment period, 35 days.</time_frame>
        <population>All randomized participants (intent-to-treat population)</population>
        <group_list>
          <group group_id="O1">
            <title>Lusutrombopag</title>
            <description>Lusutrombopag 3 mg once daily for up to 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Response</title>
          <description>A response was defined as a platelet count of ≥ 50 × 10⁹/L with an increase of ≥ 20 × 10⁹/L from Baseline at any time during the study. Participants who met this response criterion only after platelet transfusion were considered as nonresponders.</description>
          <population>All randomized participants (intent-to-treat population)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.8" lower_limit="55.0" upper_limit="73.8"/>
                    <measurement group_id="O2" value="13.1" lower_limit="7.3" upper_limit="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A gatekeeping procedure was employed for sequentially testing the prespecified important secondary endpoints, identified as the most clinically relevant endpoints. If the primary endpoint was statistically significant, the secondary endpoints were tested at the 0.05 level (2-sided) in sequence.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted for the stratification factors of platelet count at randomization and the planned primary invasive procedure.</method_desc>
            <param_type>Difference</param_type>
            <param_value>52.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>42.0</ci_lower_limit>
            <ci_upper_limit>62.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Increase in Platelet Count to ≥ 50 × 10⁹/L</title>
        <description>The duration of the increase in platelet count was defined as the number of days during which the platelet count was maintained as ≥ 50 × 10⁹/L.</description>
        <time_frame>From Day 1 to the end of the posttreatment period, 35 days.</time_frame>
        <population>All randomized participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Lusutrombopag</title>
            <description>Lusutrombopag 3 mg once daily for up to 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Increase in Platelet Count to ≥ 50 × 10⁹/L</title>
          <description>The duration of the increase in platelet count was defined as the number of days during which the platelet count was maintained as ≥ 50 × 10⁹/L.</description>
          <population>All randomized participants with available data</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.11" lower_limit="6.59" upper_limit="23.88"/>
                    <measurement group_id="O2" value="0.98" lower_limit="0.00" upper_limit="9.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A gatekeeping procedure was employed for sequentially testing the prespecified important secondary endpoints, identified as the most clinically relevant endpoints. If the primary endpoint was statistically significant, the secondary endpoints were tested at the 0.05 level (2-sided) in sequence.</non_inferiority_desc>
            <p_value>0.0002</p_value>
            <method>van Elteren test</method>
            <method_desc>van Elteren test stratified by platelet transfusion during the study.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Increase in Platelet Count to ≥ 50 × 10⁹/L by Platelet Transfusion Status</title>
        <description>The duration of the increase in platelet count was defined as the number of days during which the platelet count was maintained as ≥ 50 × 10⁹/L.</description>
        <time_frame>From Day 1 to the end of the posttreatment period, 35 days.</time_frame>
        <population>All randomized participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Lusutrombopag With Platelet Transfusion</title>
            <description>Lusutrombopag 3 mg once daily for up to 7 days in participants who received platelet transfusion.</description>
          </group>
          <group group_id="O2">
            <title>Lusutrombopag Without Platelet Transfusion</title>
            <description>Lusutrombopag 3 mg once daily for up to 7 days in participants who did not receive platelet transfusion.</description>
          </group>
          <group group_id="O3">
            <title>Placebo With Platelet Transfusion</title>
            <description>Placebo once daily for up to 7 days in participants who received platelet transfusion.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Without Platelet Transfusion</title>
            <description>Placebo once daily for up to 7 days in participants who did not receive platelet transfusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Increase in Platelet Count to ≥ 50 × 10⁹/L by Platelet Transfusion Status</title>
          <description>The duration of the increase in platelet count was defined as the number of days during which the platelet count was maintained as ≥ 50 × 10⁹/L.</description>
          <population>All randomized participants with available data</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" lower_limit="0.00" upper_limit="14.00"/>
                    <measurement group_id="O2" value="19.21" lower_limit="12.64" upper_limit="28.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="5.04"/>
                    <measurement group_id="O4" value="8.86" lower_limit="0.00" upper_limit="18.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A gatekeeping procedure was employed for sequentially testing the prespecified important secondary endpoints, identified as the most clinically relevant endpoints. If the primary endpoint was statistically significant, the secondary endpoints were tested at the 0.05 level (2-sided) in sequence.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Required Rescue Therapy for Bleeding During the Study</title>
        <description>Participants who received rescue therapy for bleeding events during the study. Platelet preparations, other blood preparations (including red blood cells and plasma), and volume expanders were considered as rescue therapy for bleeding events.</description>
        <time_frame>From Day 1 to the end of the possttreatment period, 35 days.</time_frame>
        <population>All randomized participants (intent-to-treat population)</population>
        <group_list>
          <group group_id="O1">
            <title>Lusutrombopag</title>
            <description>Lusutrombopag 3 mg once daily for up to 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Required Rescue Therapy for Bleeding During the Study</title>
          <description>Participants who received rescue therapy for bleeding events during the study. Platelet preparations, other blood preparations (including red blood cells and plasma), and volume expanders were considered as rescue therapy for bleeding events.</description>
          <population>All randomized participants (intent-to-treat population)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Specified Total Number of Platelet Transfusions</title>
        <description>The number of transfusions administered to each patient were collected over the duration of the trial. The data are presented as the number of patients with the highest total number of transfusions followed by the next highest number of transfusions, etc.</description>
        <time_frame>From Day 1 to the end of the posttreatment period, 35 days.</time_frame>
        <population>All randomized participants (intent-to-treat population)</population>
        <group_list>
          <group group_id="O1">
            <title>Lusutrombopag</title>
            <description>Lusutrombopag 3 mg once daily for up to 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Specified Total Number of Platelet Transfusions</title>
          <description>The number of transfusions administered to each patient were collected over the duration of the trial. The data are presented as the number of patients with the highest total number of transfusions followed by the next highest number of transfusions, etc.</description>
          <population>All randomized participants (intent-to-treat population)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No transfusions</title>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>One transfusion</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Two transfusions</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Three transfusions</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Four transfusions</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Five transfusions</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Platelet Count Over Time</title>
        <time_frame>Baseline and Days 5, 6, 7, 8, 10, 12, 14, 17, 21, 28, and 35.</time_frame>
        <population>All randomized participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Lusutrombopag With Platelet Transfusion</title>
            <description>Lusutrombopag 3 mg once daily for up to 7 days in participants who received platelet transfusion.</description>
          </group>
          <group group_id="O2">
            <title>Lusutrombopag Without Platelet Transfusion</title>
            <description>Lusutrombopag 3 mg once daily for up to 7 days in participants who did not receive platelet transfusion.</description>
          </group>
          <group group_id="O3">
            <title>Placebo With Platelet Transfusion</title>
            <description>Placebo once daily for up to 7 days in participants who received platelet transfusion.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Without Platelet Transfusion</title>
            <description>Placebo once daily for up to 7 days in participants who did not receive platelet transfusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Platelet Count Over Time</title>
          <population>All randomized participants with available data at each time point.</population>
          <units>* 10⁹/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="6.5"/>
                    <measurement group_id="O2" value="10.4" spread="12.5"/>
                    <measurement group_id="O3" value="0.4" spread="6.6"/>
                    <measurement group_id="O4" value="6.1" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="8.1"/>
                    <measurement group_id="O2" value="13.6" spread="15.7"/>
                    <measurement group_id="O3" value="-0.6" spread="7.0"/>
                    <measurement group_id="O4" value="6.7" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="7.9"/>
                    <measurement group_id="O2" value="20.6" spread="16.8"/>
                    <measurement group_id="O3" value="0.0" spread="7.7"/>
                    <measurement group_id="O4" value="6.7" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="9.5"/>
                    <measurement group_id="O2" value="27.4" spread="21.5"/>
                    <measurement group_id="O3" value="-0.1" spread="5.2"/>
                    <measurement group_id="O4" value="7.3" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" spread="10.6"/>
                    <measurement group_id="O2" value="36.7" spread="24.1"/>
                    <measurement group_id="O3" value="2.1" spread="11.0"/>
                    <measurement group_id="O4" value="12.7" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" spread="12.3"/>
                    <measurement group_id="O2" value="37.0" spread="18.5"/>
                    <measurement group_id="O3" value="3.1" spread="9.5"/>
                    <measurement group_id="O4" value="14.8" spread="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="62"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" spread="19.3"/>
                    <measurement group_id="O2" value="33.5" spread="19.9"/>
                    <measurement group_id="O3" value="4.0" spread="11.8"/>
                    <measurement group_id="O4" value="12.8" spread="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="61"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" spread="23.4"/>
                    <measurement group_id="O2" value="27.2" spread="21.1"/>
                    <measurement group_id="O3" value="1.9" spread="9.0"/>
                    <measurement group_id="O4" value="17.0" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="16.0"/>
                    <measurement group_id="O2" value="20.9" spread="20.3"/>
                    <measurement group_id="O3" value="2.5" spread="9.0"/>
                    <measurement group_id="O4" value="13.2" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="11.4"/>
                    <measurement group_id="O2" value="12.4" spread="18.8"/>
                    <measurement group_id="O3" value="2.0" spread="8.9"/>
                    <measurement group_id="O4" value="10.1" spread="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="6.2"/>
                    <measurement group_id="O2" value="9.4" spread="19.3"/>
                    <measurement group_id="O3" value="0.7" spread="9.1"/>
                    <measurement group_id="O4" value="6.0" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs)</title>
        <time_frame>From first dose of study drug to 28 days after the last dose, 35 days.</time_frame>
        <population>All randomized participants who received at least 1 dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Lusutrombopag</title>
            <description>Lusutrombopag 3 mg once daily for up to 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs)</title>
          <population>All randomized participants who received at least 1 dose of the study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse events with outcome of death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to discontinuation of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) of Lusutrombopag</title>
        <time_frame>Day 5, predose and 2, 4, 6, 8, 24, and 48 hours post-dose (24 and 48 hours post-dose = Day 6 and Day 7 prior to dose on that day).</time_frame>
        <population>Participants in the intensive pharmacokinetic (PK) sampling group with at least 1 PK parameter estimated.</population>
        <group_list>
          <group group_id="O1">
            <title>Lusutrombopag</title>
            <description>Lusutrombopag 3 mg once daily for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Lusutrombopag</title>
          <population>Participants in the intensive pharmacokinetic (PK) sampling group with at least 1 PK parameter estimated.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157" spread="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Plasma Concentration (Tmax) of Lusutrombopag</title>
        <time_frame>Day 5, predose and 2, 4, 6, 8, 24, and 48 hours post-dose (24 and 48 hours post-dose = Day 6 and Day 7 prior to dose on that day).</time_frame>
        <population>Participants in the intensive pharmacokinetic (PK) sampling group with at least 1 PK parameter estimated.</population>
        <group_list>
          <group group_id="O1">
            <title>Lusutrombopag</title>
            <description>Lusutrombopag 3 mg once daily for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax) of Lusutrombopag</title>
          <population>Participants in the intensive pharmacokinetic (PK) sampling group with at least 1 PK parameter estimated.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.95" lower_limit="2.03" upper_limit="7.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve Over the Dosing Interval τ (AUC0-τ) for Lusutrombopag</title>
        <time_frame>Day 5, predose and 2, 4, 6, 8, 24, and 48 hours post-dose (24 and 48 hours post-dose = Day 6 and Day 7 prior to dose on that day).</time_frame>
        <population>Participants in the intensive pharmacokinetic (PK) sampling group with at least 1 PK parameter estimated.</population>
        <group_list>
          <group group_id="O1">
            <title>Lusutrombopag</title>
            <description>Lusutrombopag 3 mg once daily for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve Over the Dosing Interval τ (AUC0-τ) for Lusutrombopag</title>
          <population>Participants in the intensive pharmacokinetic (PK) sampling group with at least 1 PK parameter estimated.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2737" spread="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Total Clearance (CL/F) of Lusutrombopag</title>
        <time_frame>Day 5, predose and 2, 4, 6, 8, 24, and 48 hours post-dose (24 and 48 hours post-dose = Day 6 and Day 7 prior to dose on that day).</time_frame>
        <population>Participants in the intensive pharmacokinetic (PK) sampling group with at least 1 PK parameter estimated.</population>
        <group_list>
          <group group_id="O1">
            <title>Lusutrombopag</title>
            <description>Lusutrombopag 3 mg once daily for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Clearance (CL/F) of Lusutrombopag</title>
          <population>Participants in the intensive pharmacokinetic (PK) sampling group with at least 1 PK parameter estimated.</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" spread="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug until 28 days after last dose, 35 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lusutrombopag</title>
          <description>Lusutrombopag 3 mg once daily for up to 7 days.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo once daily for up to 7 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Cardiac ventricular thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multiorgan failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Vessel perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA version 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Edema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shionogi Clinical Trials Administrator</name_or_title>
      <organization>Shionogi Inc.</organization>
      <phone>800-849-9707</phone>
      <email>shionogiclintrials-admin@shionogi.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

